Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides farinae allergen
- Development stage
- Unknown
- Lead developer
- Wolwo Biotech
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Dermatophagoides farinae allergen is a standardized allergen extract derived from the American house dust mite, Dermatophagoides farinae. It is primarily used in allergen-specific immunotherapy (AIT), specifically as sublingual immunotherapy (SLIT) drops, for the treatment of allergic rhinitis and allergic conjunctivitis in patients sensitized to house dust mites. The drug works by inducing peripheral immune tolerance, which involves the expansion of regulatory T cells (Tregs), the production of anti-inflammatory cytokines such as interleukin-10 (IL-10), and a shift from a Th2-mediated allergic response to a Th1-mediated response. This modulation leads to a decrease in allergen-specific IgE levels and a reduction in the activation of effector cells like mast cells and basophils. In China, this product is developed and manufactured by Zhejiang Wolwo Bio-Pharmaceutical under the brand name Chanllergen.
- Brand names
- Chanllergen
- Other names
- dermatophagoides farinae allergenAmerican house dust mite allergenDermatophagoides farinae extractDf allergen
02
Targets
Der f-specific IgE (Dermatophagoides farinae-specific IgE)Dermatophagoides farinae-specific T-cell receptors
Beyond the preview
Go deeper on dermatophagoides farinae allergen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides farinae allergen.